UK markets close in 5 hours 45 minutes

BioPorto A/S (THOXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.31000.0000 (0.00%)
At close: 11:49AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3100
Open0.3100
BidN/A x N/A
AskN/A x N/A
Day's range0.3100 - 0.3100
52-week range0.2120 - 0.4345
Volume30,000
Avg. volume0
Market cap117.694M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    First Quarter 2024: Strong growth in US sales of The NGAL Test

    May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced interim financial results for the first three months of 2024 and business progress for the first quarter of 2024. Financial Highlights For the th

  • Globe Newswire

    BioPorto A/S Appoints President and CEO of BioPorto Inc.

    May 7, 2024News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Jeffrey N. Haas as new President and Chief Executive Officer of BioPorto Inc. (US), the fully owned subsidiary of BioPorto, and member of the Group’s Executi

  • Globe Newswire

    BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting

    May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, May 2, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the first quarter ending March 31, 2024, the Company’s management team will host an online